Document Type: Original Research

Authors

1 Department of Physics, Faculty of Sciences, University of Birjand, Birjand, Iran

2 Biomedical Engineering and Medical Physics Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Background: In neutron interaction with matter and reduction of neutron energy due to multiple scatterings to the thermal energy range, increasing the probability of thermal neutron capture by neutron captures makes dose enhancement in the tumors loaded with these materials.
Objective: The purpose of this study is to evaluate dose distribution in the presence of 10B, 157Gd and 33S neutron capturers and to determine the effect of these materials on dose enhancement rate for 252Cf brachytherapy source.
Methods: Neutron-ray flux and energy spectra, neutron and gamma dose rates and dose enhancement factor (DEF) are determined in the absence and presence of 10B, 157Gd and 33S using Monte Carlo simulation.
Results: The difference in the thermal neutron flux rate in the presence of 10B and 157Gd is significant, while the flux changes in the fast and epithermal energy ranges are insensible. The dose enhancement factor has increased with increasing distance from the source and reached its maximum amount equal to 258.3 and 476.1 cGy/h/µg for 157Gd and 10B, respectively at about 8 cm distance from the source center. DEF for 33S is equal to one.
Conclusion: Results show that the magnitude of dose augmentation in tumors containing 10B and 157Gd in brachytherapy with 252Cf source will depend not only on the capture product dose level, but also on the tumor distance from the source. 33S makes dose enhancement under specific conditions that these conditions depend on the neutron energy spectra of source, the 33S concentration in tumor and tumor distance from the source.

Keywords

  1. Maruyama Y. Californium-252: New radioisotope for human cancer therapy. Endocuriether. Hyperthermia Oncol. 1986;2:171-87
  2. Schlea CS, Stoddard DH. Californium isotopes proposed for intracavity and interstitial radiation therapy with neutrons. Nature. 1965;206:1058-9. doi.org/10.1038/2061058a0. PubMed PMID: 5839071.
  3. Rorer D, Wambersie G. Current Status of neutron capture therapy. IAEA. 2001;(8):75-7.
  4. Al-Saihati I, Naqvi A. Neutron and gamma ray doses from a 252Cf brachytherapy source in a water phantom. Journal of Radioanalytical and Nuclear Chemistry. 2013;296:963-6. doi.org/10.1007/s10967-012-2172-5.
  5. Ghassoun J, Merzouki A, El Morabiti A, Jehouani A. On the 252 Cf primary and secondary gamma rays and epithermal neutron flux for BNCT. Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms. Nucl Instrum Methods Phys Res B. 2007;263:231-3. doi.org/10.1016/j.nimb.2007.04.091.
  6. Yanch JC, Zamenhof RG. Dosimetry of 252Cf sources for neutron radiotherapy with and without augmentation by boron neutron capture therapy. Radiat Res. 1992;131:249-56. doi.org/10.2307/3578413. PubMed PMID: 1438684.
  7. Ghassoun J, Mostacci D, Molinari V, Jehouani A. Detailed dose distribution prediction of Cf-252 brachytherapy source with boron loading dose enhancement. Appl Radiat Isot. 2010;68:265-70. doi.org/10.1016/j.apradiso.2009.10.004. PubMed PMID: 19889549.
  8. Wierzbicki JG, Maruyama Y, Porter AT. Measurement of augmentation of 252Cf implant by 10B and 157Gd neutron capture. Med Phys. 1994;21:787-90. doi.org/10.1118/1.597324. PubMed PMID: 7935215.
  9. Brugger RM, Shih JA. Evaluation of gadolinium-157 as a neutron capture therapy agent. Strahlenther Onkol. 1989;165:153-6. PubMed PMID: 2494719.
  10. Porras I. Enhancement of neutron radiation dose by the addition of sulphur-33 atoms. Phys Med Biol. 2008;53:L1-9. doi.org/10.1088/0031-9155/53/7/L01. PubMed PMID: 18356577.
  11. Porras I. Sulfur-33 nanoparticles: a Monte Carlo study of their potential as neutron capturers for enhancing boron neutron capture therapy of cancer. Appl Radiat Isot. 2011;69:1838-41. doi.org/10.1016/j.apradiso.2011.04.002. PubMed PMID: 21497099.
  12. MCNP, X-5. Monte Carlo Team, 2005. MCNP-A General Monte Carlo N-Particle Transport Code, Version 5. Los Alamos National Laboratory Report LA-UR-03-1987. (April 2003)
  13. Chadwick MB, Barschall HH, Caswell RS, DeLuca PM, Hale GM, Jones DT, et al. A consistent set of neutron kerma coefficients from thermal to 150 MeV for biologically important materials. Med Phys. 1999;26:974-91. doi.org/10.1118/1.598601. PubMed PMID: 10436900.
  14. Martin R, Miller J, editors. Applications of Californium-252 Neutron Sources in Medicine, Research, and Industry. Americas Nuclear Energy Symposium (ANES 2002); 2002.
  15. Fortune IV EC. Gamma and neutron dose profiles near a Cf-252 brachytherapy source. 2010.
  16. Colvett RD, Rossi HH, Krishnaswamy V. Dose distributions around a californium-252 needle. Phys Med Biol. 1972;17:356-64. doi.org/10.1088/0031-9155/17/3/302. PubMed PMID: 5070446.
  17. Krishnaswamy V. Calculated depth dose tablets for californium-252 sources in tissue. Phys Med Biol. 1972;17(1):56-63. doi.org/10.1088/0031-9155/17/1/006. PubMed PMID: 5071502.